Bioblast Pharma

Hope should not be rare

Latest Developments Archive

Latest Developments Archive

  • October 27, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast to Host Conference Call & Webcast on Tuesday, October 27 to Discuss Interim Results From HOPEMD Phase 2 Clinical Study of Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD)

Conference Call and Webcast on Tuesday, October 27th at 8:30 a.m. Eastern Time

New Haven, CT and Tel Aviv, Israel – October 26, 2015 – Bioblast Pharma Ltd.,(NasdaqGM: ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced that it will report the interim Phase 2 clinical study results of Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) on Tuesday, October 27th. Company management will host a conference call & webcast at 8:30am Eastern Time.

Conference Call and Webcast Information

Tuesday, October 27 at 8:30a.m. Eastern Time

US Toll-free 1-888-378-4361
International 1-719-457-2644
Conference ID 124818
Webcast https://public.viavid.com/index.php?id=116661

Continue reading

  • October 9, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Augments Leadership Team

Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer

New Haven, CT – October 9, 2015 – Bioblast Pharma Ltd., (NasdaqGM: ORPN), a clinical stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that it has appointed Theresa (Terri) Stevens to the newly-created position of Chief Corporate Development Officer (CCDO). Ms. Stevens will be a member of Bioblast’s Executive Committee and will oversee, in particular, the corporate strategy, M&A, and business development of marketed and development stage in- and out-licensing.

Continue reading

  • September 16, 2015
  • Bioblast Pharma
  • Latest developments

Bioblast Pharma Announces Appointment of Tom Dubin, Former Alexion SVP & Chief Legal Officer, to the Board of Directors

New Haven, CT – September 16, 2015 – Bioblast Pharma Ltd., (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that Tom Dubin has joined its Board of Directors, effective immediately.
“Given Tom’s significant operating, reimbursement, and legal experience, especially in the orphan drug arena, and as a member of the Executive Committee of Alexion, there is no doubt he will be a tremendous asset to us, as we seek to develop and commercialize our product platforms. We are very pleased to welcome Tom to our Board of Directors,” said Fredric Price, Executive Chairman of Bioblast.

Continue reading

Pages